Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography

NCT03842839•Guangzhou Institute of Respiratory Disease

Summary

The study aims to explore the effect of tiotropium on airway remodeling by using Endobronchial Optical Coherence Tomography (EB-OCT). We enrolled patients with GOLD I stage COPD. All the patients will be divided into four groups randomly to receive SABA as needed with or without regular use of tiotropium. Changes of airway morphology (accessed by EB-OCT), pulmonary function, QOL, and SABA usage will be obtained.

Eligibility

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Over 40 yrs; Male or female Diagnosed with COPD
•Pre-bronchodilator FEV1 ≥80% pred ;
•Patients must be able to perform all study related procedures

Exclusion Criteria

•Patients with other lung diseases (such as bronchiectasis, pneumothorax, pleural effusion, airway deformation, lung surgery, etc.).
•Patients have poor compliance and are unwilling to receive medication regularly.
•Other complications of bronchoscopy or intolerance of bronchoscopy procedure.

Locations (1)

Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Key Dates

Start Date

October 1, 2018

Primary Completion Date

December 1, 2022

Completion Date

December 1, 2022

Last Updated

September 29, 2022

Enrollment

100

ESTIMATED participants

Conditions

Airway Remodeling

Interventions

Tiotropium Inhalation Powder [Spiriva] 0.018mg

DRUG

Salbutamol sulphate aerosol (Ventolin) 0.01mg

DRUG

Feasibility of Tracheobronchial Defect Reconstruction Using Allogenic Aortic Patch

NCT06935110

Trachea DiseasesAirway Remodeling+1 more

View study

COMPLETED

Observational Study With Investigation of Two Second Generation Laryngeal Masks

NCT02566291

Airway Remodeling

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 29, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions